RealFeedApp beta
- Clinical trials for CAR T-cell therapies halted
Shares of CRISPR genome-editing firm Caribou fell 62% after announcing workforce reductions and pausing trials for two allogeneic CAR-T therapies. The company's staff numbered 97 people as of February 27.
- Field
- business and funding
- What they did
- Caribou Biosciences announced plans to cut its workforce by 97 employees and pause clinical trials, causing its stock price to drop 62%.
- Why it matters
- Investors sold off shares due to concerns about the company's financial stability and the scale of layoffs, even though the CEO stated the decision does not reflect a loss of faith in their science.
#caribou biosciences#crispr#car-t therapy#clinical trial#stock market
